Insomnia in patients with schizophrenia
Conditions
Interventions
Administration of 5 mg of Lemborexant for 14 days
14 days of placebo administration
Sponsors
Department of Psychiatry, Kurita Hospital, 695 Kurita Nagano-City Nagano, Japan, 380-0921
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Satisfy DSM5 diagnostic criteria for schizophrenia 2. Being treated in Kurita hospital 3.Those aged between 20 and 70. 4.Satisfy DSM5 diagnostic criteria for insomnia. 5.Using one or less benzodiazepines. 6.Not taking orexin receptor antagonists.
Exclusion criteria
Exclusion criteria: 1.Coexisting with mood disorder, anxiety disorder, drug addiction, or personality disorder. 2.Suffering from serious physical diseases such as cerebrovascular disease, heart disease, renal dysfunction, and neurological disease. 3.Coexisting with other sleep disorders such as hypersomnia, sleep-related breathing disorders, circadian rhythm sleep disorders, parasomnia, and sleep-related movement disorders. 4.Actigraphy cannot be performed safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep variables obtained from actigraphs. Comparison between the 7-day pre-observation period and the 7th to 13th days after the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between change from baseline in sleep variables obtained from Actigraphs and blood orexin A levels at night. | — |
Countries
Japan
Contacts
Public ContactYusuke Arai
Kurita Hospital Department of Psychiatry
Outcome results
None listed